Home › Funds › Callahan Advisors, LLC › ABT
Callahan Advisors, LLC position in ABT
ABBOTT LABORATORIES · Health Care
Callahan Advisors, LLC reported holding 86,921 shares of ABT (ABBOTT LABORATORIES) in its Q3 2026 13F filing — a position valued at US$8.6M, representing 0.66% of its reported portfolio and ranking #45 among its reported holdings. Callahan Advisors, LLC has disclosed ABT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Callahan Advisors, LLC's ABT position evolved
Callahan Advisors, LLC first disclosed a stake in ABT in Q3 2023 at 81,887 shares (US$7.9M). The position peaked in Q2 2025 at 84,230 shares, worth US$11.5M. Across 13 filings, Callahan Advisors, LLC increased the stake 5 time(s), trimmed it 5 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 86,921 shares valued at US$8.6M — an increase of 10,978 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 81.89K | $7.93M | New |
| Q4 2023 | 79.80K | $8.78M | Reduce |
| Q1 2024 | 73.90K | $8.40M | Reduce |
| Q2 2024 | 73.16K | $7.60M | Reduce |
| Q3 2024 | 74.42K | $8.48M | Add |
| Q4 2024 | 84.44K | $9.55M | Add |
| Q1 2025 | 84.15K | $11.16M | Hold |
| Q2 2025 | 84.23K | $11.46M | Hold |
| Q3 2025 | 85.03K | $11.39M | Add |
| Q4 2025 | 83.80K | $10.50M | Reduce |
| Q1 2026 | 74.90K | $7.69M | Reduce |
| Q2 2026 | 75.94K | $6.89M | Add |
| Q3 2026 | 86.92K | $8.59M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ABT and 13F data
ABT (ABBOTT LABORATORIES) is a Health Care company. 21 other funds we track also report a position in ABT — the largest reported positions include Vanguard Group (US$22.00B), Charles Schwab Investment Management (US$5.41B), CHARLES SCHWAB INVESTMENT MANAGEMENT INC (US$5.41B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ABT
- Vanguard Group 175.56M sh · $22.00B · Q4 2025
- Charles Schwab Investment Management 59.67M sh · $5.41B · Q2 2026
- CHARLES SCHWAB INVESTMENT MANAGEMENT INC 59.67M sh · $5.41B · Q2 2026
- Capital Research Global Investors 44.98M sh · $4.45B · Q3 2026
- Capital International Investors 35.46M sh · $3.51B · Q3 2026
- Capital Research Global Investors 36.91M sh · $3.35B · Q2 2026
- Franklin Resources 20.44M sh · $2.36B · Q3 2026
- Deutsche Bank AG 17.69M sh · $1.75B · Q3 2026
- MFS Investment Management 14.93M sh · $1.48B · Q3 2026
More on Callahan Advisors, LLC
FAQ
How long has Callahan Advisors, LLC held ABT?
Callahan Advisors, LLC has disclosed ABT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is Callahan Advisors, LLC's current position in ABT?
As of Q3 2026, Callahan Advisors, LLC holds 86.92K shares of ABT (ABBOTT LABORATORIES), valued at $8.59M, representing 0.66% of its reported portfolio and ranking #45.
Has Callahan Advisors, LLC been buying or selling ABT?
In the latest 13F filing (Q3 2026), Callahan Advisors, LLC increased its position in ABT. The position peaked in Q2 2025 at 84.23K shares.
Which other funds hold ABT?
Other major institutional holders of ABT include Vanguard Group, Charles Schwab Investment Management, CHARLES SCHWAB INVESTMENT MANAGEMENT INC, among 21 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.